Skip to main content
NCBI home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2005 Sep 20;6(1):E100–E107. doi: 10.1208/pt060116

Eudragit S100 entrapped insulin microspheres for oral delivery

Deepti Jain 1, Amulya K Panda 2, Dipak K Majumdar 1,✉
PMCID: PMC2750417  PMID: 16353953

Abstract

The purpose of this research was to investigate whether Eudragit S100 microspheres have the potential to serve as an oral carrier for peptide drugs like insulin. Microspheres were prepared using water-in oil-in water emulsion solvent evaporation technique with polysorbate 20 as a dispersing agent in the internal aqueous phase and polyvinyl alcohol (PVA)/polyvinyl pyrrolidone as a stabilizer in the external aqueous phase. The use of smaller internal aqueous-phase volume (50 μL) and external aqueous-phase volume (25 mL) containing PVA in the manufacturing process resulted in maximum encapsulation efficiency (81.8%±0.9%). PVA-stabilized microspheres having maximum drug encapsulation released 2.5% insulin at pH 1.0 in 2 hours. In phosphate buffer (pH 7.4), microspheres showed an initial burst release of 22% in 1 hour with an additional 28% release in the next 5 hours. The smaller the volumes of internal and external aqueous phase, the lower the initial burst release. The release of drug from microspheres followed Higuchi kinetics. Scanning electron microscopy of PVA-stabilized microspheres demonstrated spherical particles with smooth surface, and laser diffractometry revealed a mena particle size of 32.51±20 μm. Oral administration of PVA stabilized microspheres in normal albino rabbits (equivalent to 6.6 IU insulin/kg of animal weight) demonstrated a 24% reduction in blood glucose level, with maximum plasma glucose reduction of 76±3.0% in 2 hours and effect continuing up to 6 hours. The area under the percentage glucose reduction-time curve was 93.75%. Thus, our results indicate that Eudragit S100 microspheres on oral administration can protect insulin from proteolytic degradation in the gastrointestinal tract and produce hypoglycemic effect.

Keywords: insulin, oral, Eudragit S100, microspheres, hypoglycaemic

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Footnotes

formerly College of Pharmacy, University of Delhi, Pushp Vihar, Sector-III, New Delhi-110017, India

References

  • 1.Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90:261–280. doi: 10.1016/S0168-3659(03)00194-9. [DOI] [PubMed] [Google Scholar]
  • 2.Lee VC, Yalkowsky SH. Ocular devices for the controlled systemic delivery of insulin: in vitro and in vivo dissolution. Int J Pharm. 1999;181:71–77. doi: 10.1016/S0378-5173(98)00418-9. [DOI] [PubMed] [Google Scholar]
  • 3.Pillion DJ, Atchison JA, Stott J, McCracken D, Gargiulo C. Meezan E. Efficacy of insulin eye drops. J Ocul Pharmacol. 1994;10:461–470. doi: 10.1089/jop.1994.10.461. [DOI] [PubMed] [Google Scholar]
  • 4.Mitra R, Pezron I, Chu WA, Mitra AK. Lipid emulsions as vehicles for enhanced nasal delivery of insulin. Int J Pharm. 2002;205:127–134. doi: 10.1016/S0378-5173(00)00506-8. [DOI] [PubMed] [Google Scholar]
  • 5.Morishita M, Barichello JM, Takayama K, Chiba Y, Tokiwa S, Nagai T. Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. Int J Pharm. 2001;212:289–293. doi: 10.1016/S0378-5173(00)00615-3. [DOI] [PubMed] [Google Scholar]
  • 6.Yang TZ, Wang XT, Yan XY, Zhang Q. Phospholipid deformable vesicles for buccal delivery of insulin. Chem Pharm Bull. 2002;50:749–753. doi: 10.1248/cpb.50.749. [DOI] [PubMed] [Google Scholar]
  • 7.Hosny E, el-Ahmady O, el-Shattawy H, et al. Effect of sodium salicylate on insulin rectal absorption in humans. Arzneimittelforschung. 1994;44:611–613. [PubMed] [Google Scholar]
  • 8.Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62:279–287. doi: 10.1016/S0168-3659(99)00048-6. [DOI] [PubMed] [Google Scholar]
  • 9.Steiner S, Pfutzner A, Wilson BR, Harzer O, Heinemann L, Rane K. Technosphere/Insulin—proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110:17–21. doi: 10.1055/s-2002-19989. [DOI] [PubMed] [Google Scholar]
  • 10.Hosny EA, Al-Shora HI, Elmazar MA. Oral delivery of insulin from enteric coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. Int J Pharm. 2002;237:71–76. doi: 10.1016/S0378-5173(02)00024-8. [DOI] [PubMed] [Google Scholar]
  • 11.Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J Control Release. 2000;65:261–269. doi: 10.1016/S0168-3659(99)00247-3. [DOI] [PubMed] [Google Scholar]
  • 12.Damge C, Vranchx H, Balschmidt P, Couvreur P. Poly (alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci. 1997;86:1403–1409. doi: 10.1021/js970124i. [DOI] [PubMed] [Google Scholar]
  • 13.Kimura T, Sato K, Sugimoto K, et al. Oral administration of insulin as poly(vinyl alcohol)-gel spheres in diabetic rats. Biol Pharm Bull. 1996;19:897–900. doi: 10.1248/bpb.19.897. [DOI] [PubMed] [Google Scholar]
  • 14.Mesiha M, Sidhom M. Increased oral absorption enhancement of insulin by medium viscosity hydroxypropyl cellulose. Int J Pharm. 1995;114:137–140. doi: 10.1016/0378-5173(94)00229-X. [DOI] [Google Scholar]
  • 15.Scott-Moncrieff JC, Shao Z, Mitra AK. Enhancement of intestinal insulin absorption by bile salt-fatty acid mixed micelles in dogs. J Pharm Sci. 1994;83:1465–1469. doi: 10.1002/jps.2600831020. [DOI] [PubMed] [Google Scholar]
  • 16.Qi R, Ping QN. Gastrointestinal absorption enhancement of insulin by administration of enteric microspheres and SNAC to rats. J Microencapsul. 2004;21:37–45. doi: 10.1080/02652040410001653786. [DOI] [PubMed] [Google Scholar]
  • 17.Nishihata T, Higuchi T, Kamada A. Salicylate promoted permeation of cefoxitin, insulin and phenylalanine across red cell membrane: Possible mechanism. Life Sci. 1984;34:437–445. doi: 10.1016/0024-3205(84)90498-3. [DOI] [PubMed] [Google Scholar]
  • 18.Kajii T, Hori T, Hayashi M, Awazu S. Effect of salicylic acid on the permeability of plasma membrane of small intestine of the rat: Fluorescence spectroscopic approval to elucidate the mechanism of promoted drug absorption. J Pharm Sci. 1986;75:475–478. doi: 10.1002/jps.2600750511. [DOI] [PubMed] [Google Scholar]
  • 19.Susuka T, Tata N, Sakai K, Nishihata T. The effect of salicylate concentration on the uptake of salicylate and cefmetazole into rat isolated small intestine epithelial cells. J Pharm Pharmacol. 1988;40:469–472. doi: 10.1111/j.2042-7158.1988.tb05279.x. [DOI] [PubMed] [Google Scholar]
  • 20.Insel PA. Analgesic, antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's—The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. [Google Scholar]
  • 21.Rosa GD, Iommelli R, Rotonda MIL, Miro A, Quaglia F. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J Control Release. 2000;69:283–295. doi: 10.1016/S0168-3659(00)00315-1. [DOI] [PubMed] [Google Scholar]
  • 22.Lee JH, Park TG, Lee YB, Shin SC, Choi HK. Effect of adding non-volatile oil as a core material for the floating microspheres prepared by emulsion solvent diffusion method. J Microencapsul. 2001;18:65–75. doi: 10.1080/026520401750038610. [DOI] [PubMed] [Google Scholar]
  • 23.Paul W, Nesamony J, Sharma CP. Delivery of insulin from hydroxyapatite ceramic microspheres: Preliminary in-vivo studies. J Biomed Mater Res. 2002;61:660–662. doi: 10.1002/jbm.10213. [DOI] [PubMed] [Google Scholar]
  • 24.Uchida T, Nagareya N, Sakakibara S, et al. Preparation and characterization of polylactic acid microspheres containing bovine insulin by w/o/w emulsion solvent evaporation method. Chem Pharm Bull. 1997;45:1539–1543. doi: 10.1248/cpb.45.1539. [DOI] [PubMed] [Google Scholar]
  • 25.Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982. pp. 189–189. [Google Scholar]
  • 26.Shargel L, Yu A. Applied Biopharmaceutics & Pharmacokinetics. 4th ed. London, United Kingdom: Prentice-Hall International, Inc; 1999. pp. 173–173. [Google Scholar]
  • 27.Coombes AGA, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly (DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in-oil-in-water method. J Control Release. 1998;52:311–320. doi: 10.1016/S0168-3659(98)00006-6. [DOI] [PubMed] [Google Scholar]
  • 28.Sajeesh S, Sharma CP. Polymethacrylic acid-alginate semi-IPN microparticles for oral delivery of insulin: a preliminary in vestigation. J Biomater Appl. 2004;19:35–45. doi: 10.1177/0885328204042992. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES